{
    "id": "5880bed9-3a9c-b251-bfc1-9b0c694c8090",
    "indications": "divalproex sodium extended-release tablet indicated : acute treatment manic mixed episodes associated bipolar disorder , without psychotic features ( 1.1 ) monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1.2 ) prophylaxis migraine headaches ( 1.3 )",
    "contraindications": "divalproex sodium extended-release tablet extended-release product intended once-a-day oral . divalproex sodium extended-release tablets swallowed whole crushed chewed .",
    "warningsAndPrecautions": "divalproex sodium extended-release tablets usp , 250 mg available white white , round shaped , beveled edge , biconvex coated tablets debossed “ r ” one side “ 533 ” side . divalproex sodium extended-release tablet contains divalproex sodium equivalent 250 mg valproic acid supplied bottles 30 ’ , 60 ’ , 100 ’ , 500 ’ unit dose package 100 ( 10 x 10 ) . bottles 30 ndc 55111-533-30 bottles 60 ndc 55111-533-60 bottles 100 ndc 55111-533-01 bottles 500 ndc 55111-533-05 unit dose package 100 ( 10 x 10 ) ndc 55111-533-78 recommended storage store tablets 20°-25°c ( 68°-77°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "divalproex sodium extended-release tablets administered patients hepatic disease significant hepatic dysfunction [ seewarnings ( 5.1 ) ] . divalproex sodium extended-release tablets contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase γ ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . divalproex sodium extended-release tablets contraindicated patients known hypersensitivity . [ ( 5.12 ) ] . divalproex sodium extended-release tablets contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . prophylaxis migraine headaches : divalproex sodium extended-release tablets contraindicated women pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "ingredients": [
        {
            "name": "divalproex sodium",
            "code": "644VL95AO6"
        },
        {
            "name": "hypromelloses",
            "code": "3NXW29V3WO"
        },
        {
            "name": "hydroxyethyl cellulose (2000 CPS AT 1%)",
            "code": "S38J6RZN16"
        },
        {
            "name": "lactose monohydrate",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "cellulose, microcrystalline",
            "code": "OP1R32D61U"
        },
        {
            "name": "silicon dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "titanium dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        }
    ],
    "organization": "Dr. Reddy's Laboratories Ltd",
    "name": "Divalproex Sodium",
    "effectiveTime": "20250320",
    "indications_original": "Divalproex sodium extended-release tablet is indicated for: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features (1.1) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1.2) Prophylaxis of migraine headaches (1.3)",
    "contraindications_original": "Divalproex sodium extended-release tablet is an extended-release product intended for once-a-day oral administration. Divalproex sodium extended-release tablets should be swallowed whole and should not be crushed or chewed.",
    "warningsAndPrecautions_original": "Divalproex sodium extended-release tablets USP, 250 mg are available as white to off white, round shaped, beveled edge, biconvex coated tablets debossed “R” on one side and “533” on other side. Each divalproex sodium extended-release tablet contains divalproex sodium equivalent to 250 mg of valproic acid and are supplied in bottles of 30’s, 60’s, 100’s, 500’s and unit dose package of 100 (10 x 10).      \n                  Bottles of 30                                                                           NDC 55111-533-30\n                  Bottles of 60                                                                           NDC 55111-533-60\n                  \n                     Bottles of 100                                                                         NDC 55111-533-01\n                  \n                     Bottles of 500                                                                         NDC 55111-533-05\n                  Unit dose package of 100 (10 x 10)                                       NDC 55111-533-78\n                  \n                  \n                     Recommended Storage\n                  \n                  Store tablets at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Divalproex sodium extended-release tablets should not be administered to patients with hepatic disease or significant hepatic dysfunction [seeWarnings and Precautions  (5.1)\n                        ].\n                     Divalproex sodium extended-release tablets are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].\n                     Divalproex sodium extended-release tablets are contraindicated in patients with known hypersensitivity to the drug. [see Warnings and Precautions \n                        \n                           (5.12)\n                        ].\n                     Divalproex sodium extended-release tablets are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions \n                        \n                           (5.6)\n                        ].\n                     For use in prophylaxis of migraine headaches: Divalproex sodium extended-release tablets are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2,  5.3,  5.4) and Use in Specific Populations  (8.1)\n                        ]."
}